(BIM) Biomerieux - Performance 19.8% in 12m
Compare BIM with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
12.21%
#29 in Group
Rel. Strength
74.72%
#2018 in Universe
Total Return 12m
19.77%
#42 in Group
Total Return 5y
8.84%
#39 in Group
P/E 31.0
73th Percentile in Group
P/E Forward 24.2
73th Percentile in Group
PEG 1.45
88th Percentile in Group
FCF Yield 1.52%
83th Percentile in Group
12m Total Return: BIM (19.8%) vs XBI (-1.8%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
UTHR NASDAQ United Therapeutics |
-1.68% | 29.3% | 171% | 12.1 | 10.6 | 1.43 | 81.5% | 18.5% |
HLN NYSE Haleon |
-0.23% | 21% | 41.1% | 24.4 | 20.2 | 1.79 | 64.4% | 6.58% |
AMGN NASDAQ Amgen |
-6.62% | 9.44% | 46.9% | 37 | 13.4 | 0.94 | -42.0% | -25.9% |
LONN SW Lonza |
8.56% | 16.2% | 38.7% | 60.7 | 31.7 | 1.15 | 12.6% | -10.3% |
BIM PA Biomerieux |
3.94% | 19.8% | 8.84% | 31 | 24.2 | 1.45 | -58.7% | -25.1% |
NBIX NASDAQ Neurocrine Biosciences |
-2.63% | -21.7% | 8.36% | 32.4 | 21.5 | 0.27 | 64.4% | 51.8% |
KMDA NASDAQ Kamada |
-2.12% | 27.5% | -10.6% | 26.6 | 24 | 0.96 | 80.4% | 43% |
ERF PA Eurofins Scientific SE |
14% | -1.49% | 17.2% | 26.6 | 13.6 | 0.56 | -67.4% | -17.7% |
Performance Comparison: BIM vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for BIM
Total Return (including Dividends) | BIM | XBI | S&P 500 |
---|---|---|---|
1 Month | 3.94% | 2.28% | -0.87% |
3 Months | 1.37% | -10.48% | -7.58% |
12 Months | 19.77% | -1.83% | 11.88% |
5 Years | 8.84% | -12.72% | 110.33% |
Trend Score (consistency of price movement) | BIM | XBI | S&P 500 |
1 Month | 12.1% | 56.6% | 23% |
3 Months | 5.0% | -89.3% | -88.5% |
12 Months | 85.2% | -42.4% | 55.1% |
5 Years | -25.7% | -53.6% | 84.1% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #97 | 1.62% | 4.85% |
3 Month | #47 | 13.2% | 9.68% |
12 Month | #43 | 22.0% | 7.05% |
5 Years | #40 | 24.7% | -48.3% |
FAQs
Does BIM Biomerieux outperforms the market?
Yes,
over the last 12 months BIM made 19.77%, while its related Sector, the SPDR S&P Biotech (XBI) made -1.83%.
Over the last 3 months BIM made 1.37%, while XBI made -10.48%.
Over the last 3 months BIM made 1.37%, while XBI made -10.48%.
Performance Comparison BIM vs Indeces and Sectors
BIM vs. Indices BIM is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 1.01% | 4.81% | 17.7% | 7.89% |
US NASDAQ 100 | QQQ | -0.02% | 2.54% | 17.2% | 7.10% |
US Dow Jones Industrial 30 | DIA | 1.95% | 7.12% | 17.8% | 10.6% |
German DAX 40 | DAX | 2.24% | 2.62% | -1.86% | -4.91% |
Shanghai Shenzhen CSI 300 | CSI 300 | 4.97% | 6.76% | 20.7% | 13.8% |
Hongkong Hang Seng | HSI | 2.0% | 3.88% | 15.7% | 5.88% |
India NIFTY 50 | INDA | 3.85% | -0.12% | 17.4% | 16.7% |
Brasil Bovespa | EWZ | 1.81% | -0.66% | 14.0% | 25.6% |
BIM vs. Sectors BIM is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 0.76% | 4.99% | 11.5% | -4.19% |
Consumer Discretionary | XLY | 0.93% | 4.04% | 15.2% | 6.45% |
Consumer Staples | XLP | 4.51% | 3.74% | 12.4% | 8.57% |
Energy | XLE | 5.49% | 17.8% | 23.5% | 30.9% |
Financial | XLF | 2.40% | 6.05% | 10.1% | -2.92% |
Health Care | XLV | 1.09% | 7.73% | 19.4% | 18.1% |
Industrial | XLI | 0.59% | 3.83% | 17.0% | 10.2% |
Materials | XLB | 1.62% | 6.37% | 25.1% | 23.3% |
Real Estate | XLRE | 2.53% | 5.25% | 18.6% | 1.68% |
Technology | XLK | -1.44% | 2.25% | 21.0% | 12.0% |
Utilities | XLU | 3.85% | 3.88% | 15.5% | -2.06% |
Aerospace & Defense | XAR | 0.06% | -2.45% | 4.13% | -6.80% |
Biotech | XBI | -0.29% | 1.66% | 30.3% | 21.6% |
Homebuilder | XHB | 1.70% | 6.21% | 32.5% | 26.8% |
Retail | XRT | 2.58% | 4.50% | 23.2% | 22.5% |